J&J Innovation Announces Opening of Offices - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

J&J Innovation Announces Opening of Offices



Johnson & Johnson (J&J) Innovation, a division of J&J reported the formation of a network of partnering offices across UK life science clusters. The offices function as extensions of its London Innovation Center to work with academics and entrepreneurs throughout the UK to identify early-stage innovation and support the translation of research into new products for patients.

While the London Innovation Center continues to be the primary hub for interactions with the academic and entrepreneurial community in the greater London area, these new partnering offices are part of a broader strategy to interact
more directly with life science “hotspots” throughout the UK and Europe. Johnson & Johnson Innovation is establishing partnering offices in the following locations that will function as a base for interactions throughout the regions:

  • Babraham Research Campus for the wider Cambridge area
  • University of Oxford Old Road Campus for the wider Oxford area
  • The University of Manchester Innovation Center (UMIC) for the North and Midlands
  • Edinburgh BioQuarter for Scotland and Northern Irelan
  • Life Sciences Hub Wales in Cardiff for Wales and the South West.

Representatives from the J&J Innovation Center in London will establish a regular presence in each of the partnering offices that are expected to be fully operational in early 2014.

Johnson & Johnson Innovation focuses on accelerating early innovation and enhancing opportunities for collaboration and investment across Johnson & Johnson’s global healthcare businesses.

Source: Johnson & Johnson

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here